Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 119 entries
Sorted by: Best Match Show Resources per page
Acknowledgments - OOTR Annual Conference 2012 Proceedings.

The International journal of biological markers

Toi M.
PMID: 23334792
Int J Biol Markers. 2013 Jan 19;27(4):285. doi: 10.5301/JBM.2013.10605. Epub 2013 Jan 19.

It gives me great pleasure to announce the successful conclusion of the OOTR 8th Annual Conference, which was held on 20 and 21 April 2012 at the Westin Miyako Hotel, Kyoto, Japan. Since its last conference in Hong Kong...

Cite
Toi M. Acknowledgments - OOTR Annual Conference 2012 Proceedings. Int J Biol Markers. 2013;27(4):285doi: 10.5301/JBM.2013.10605.
Toi, M. (2013). Acknowledgments - OOTR Annual Conference 2012 Proceedings. The International journal of biological markers, 27(4), 285. https://doi.org/10.5301/JBM.2013.10605
Toi, Masakazu. "Acknowledgments - OOTR Annual Conference 2012 Proceedings." The International journal of biological markers vol. 27,4 (2013): 285. doi: https://doi.org/10.5301/JBM.2013.10605
Toi M. Acknowledgments - OOTR Annual Conference 2012 Proceedings. Int J Biol Markers. 2013 Jan 19;27(4):285. doi: 10.5301/JBM.2013.10605. Epub 2013 Jan 19. PMID: 23334792.
Copy Download .nbib Format: NLM
Relationship between GSTP1 rs1695 gene polymorphism and myelosuppression induced by platinum-based drugs: a meta-analysis.

The International journal of biological markers

Lv F, Ma Y, Zhang Y, Li Z.
PMID: 30238837
Int J Biol Markers. 2018 Nov;33(4):364-371. doi: 10.1177/1724600818792897. Epub 2018 Sep 21.

Although many previous studies have reported the relationship between GSTP1 rs1695 gene polymorphism and myelosuppression induced by platinum-based drugs, the conclusions are not consistent. The aim of the study is to evaluate the association between granulocytopenia and thrombocytopenia induced...

Cite
Lv F, Ma Y, Zhang Y, et al. Relationship between GSTP1 rs1695 gene polymorphism and myelosuppression induced by platinum-based drugs: a meta-analysis. Int J Biol Markers. 2018;33(4):364-371doi: 10.1177/1724600818792897.
Lv, F., Ma, Y., Zhang, Y., & Li, Z. (2018). Relationship between GSTP1 rs1695 gene polymorphism and myelosuppression induced by platinum-based drugs: a meta-analysis. The International journal of biological markers, 33(4), 364-371. https://doi.org/10.1177/1724600818792897
Lv, Fei, et al. "Relationship between GSTP1 rs1695 gene polymorphism and myelosuppression induced by platinum-based drugs: a meta-analysis." The International journal of biological markers vol. 33,4 (2018): 364-371. doi: https://doi.org/10.1177/1724600818792897
Lv F, Ma Y, Zhang Y, Li Z. Relationship between GSTP1 rs1695 gene polymorphism and myelosuppression induced by platinum-based drugs: a meta-analysis. Int J Biol Markers. 2018 Nov;33(4):364-371. doi: 10.1177/1724600818792897. Epub 2018 Sep 21. PMID: 30238837.
Copy Download .nbib Format: NLM
Remembering Judah Moses Folkma.

The International journal of biological markers

Gasparini G.
PMID: 28207107
Int J Biol Markers. 2008 Jan - Mar;23(1):63. doi: 10.5301/JBM.2008.5002.

Judah Moses Folkman, M.D., director of the Vascular Biology Program at Childrens Hospital and Julia Dyckman Andrus Professor of Pediatric Surgery at Harvard Medical School, Boston, died suffering a heart attack at Denver Airport on January 14, 2008, at...

Cite
Gasparini G. Remembering Judah Moses Folkma. Int J Biol Markers. 2008;23(1):63doi: 10.5301/JBM.2008.5002.
Gasparini, G. (2008). Remembering Judah Moses Folkma. The International journal of biological markers, 23(1), 63. https://doi.org/10.5301/JBM.2008.5002
Gasparini, G. "Remembering Judah Moses Folkma." The International journal of biological markers vol. 23,1 (2008): 63. doi: https://doi.org/10.5301/JBM.2008.5002
Gasparini G. Remembering Judah Moses Folkma. Int J Biol Markers. 2008 Jan - Mar;23(1):63. doi: 10.5301/JBM.2008.5002. PMID: 28207107.
Copy Download .nbib Format: NLM
Foreword.

The International journal of biological markers

Gasparini G.
PMID: 28207109
Int J Biol Markers. 2007 S4 - Jan-Mar;22(4):1-2. doi: 10.5301/JBM.2008.2635.

No abstract.

Cite
Gasparini G. Foreword. Int J Biol Markers. 2007;22(4):1-2doi: 10.5301/JBM.2008.2635.
Gasparini, G. (2007). Foreword. The International journal of biological markers, 22(4), 1-2. https://doi.org/10.5301/JBM.2008.2635
Gasparini, G. "Foreword." The International journal of biological markers vol. 22,4 (2007): 1-2. doi: https://doi.org/10.5301/JBM.2008.2635
Gasparini G. Foreword. Int J Biol Markers. 2007 S4 - Jan-Mar;22(4):1-2. doi: 10.5301/JBM.2008.2635. PMID: 28207109.
Copy Download .nbib Format: NLM
Development and clinical indications of cetuximab.

The International journal of biological markers

Labianca R, La Verde N, Garassino MC.
PMID: 28207113
Int J Biol Markers. 2007 S4 - Jan-Mar;22(4):40-46. doi: 10.5301/JBM.2008.4051.

Cetuximab is a chimeric immunoglobulin G1 monoclonal antibody that targets the extracellular domain of the epidermal growth factor receptor (EGFR) with high specificity and affinity. It competitively inhibits endogenous ligand binding and thereby inhibits subsequent EGFR activation. The EGFR...

Cite
Labianca R, La Verde N, Garassino MC. Development and clinical indications of cetuximab. Int J Biol Markers. 2007;22(4):40-46doi: 10.5301/JBM.2008.4051.
Labianca, R., La Verde, N., & Garassino, M. C. (2007). Development and clinical indications of cetuximab. The International journal of biological markers, 22(4), 40-46. https://doi.org/10.5301/JBM.2008.4051
Labianca, R, et al. "Development and clinical indications of cetuximab." The International journal of biological markers vol. 22,4 (2007): 40-46. doi: https://doi.org/10.5301/JBM.2008.4051
Labianca R, La Verde N, Garassino MC. Development and clinical indications of cetuximab. Int J Biol Markers. 2007 S4 - Jan-Mar;22(4):40-46. doi: 10.5301/JBM.2008.4051. PMID: 28207113.
Copy Download .nbib Format: NLM
Erratum in Int J Biol Markers 2007; 22(3): 226-231.

The International journal of biological markers

Vecchiet J, Castellani ML, Theoharides TC, Conti P, Patruno A, Shaik YB, Grilli A, De Lutiis MA, Mastrangelo F, Speranza L, Tete' S, Felaco M, Madhappan B, Conti F.
PMID: 28207121
Int J Biol Markers. 2007 Oct-Dec;22(4):312. doi: 10.5301/JBM.2008.1370.

Errata Corrige. In the article 'Localization and activity of iNOS in normal human lung tissue and lung cancer tissue' by Speranza L et al, which was published in the July-September issue of the International Journal of Biological Markers (Int...

Cite
Vecchiet J, Castellani ML, Theoharides TC, et al. Erratum in Int J Biol Markers 2007; 22(3): 226-231. Int J Biol Markers. 2007;22(4):312doi: 10.5301/JBM.2008.1370.
Vecchiet, J., Castellani, M. L., Theoharides, T. C., Conti, P., Patruno, A., Shaik, Y. B., Grilli, A., De Lutiis, M. A., Mastrangelo, F., Speranza, L., Tete', S., Felaco, M., Madhappan, B., & Conti, F. (2007). Erratum in Int J Biol Markers 2007; 22(3): 226-231. The International journal of biological markers, 22(4), 312. https://doi.org/10.5301/JBM.2008.1370
Vecchiet, J, et al. "Erratum in Int J Biol Markers 2007; 22(3): 226-231." The International journal of biological markers vol. 22,4 (2007): 312. doi: https://doi.org/10.5301/JBM.2008.1370
Vecchiet J, Castellani ML, Theoharides TC, Conti P, Patruno A, Shaik YB, Grilli A, De Lutiis MA, Mastrangelo F, Speranza L, Tete' S, Felaco M, Madhappan B, Conti F. Erratum in Int J Biol Markers 2007; 22(3): 226-231. Int J Biol Markers. 2007 Oct-Dec;22(4):312. doi: 10.5301/JBM.2008.1370. PMID: 28207121.
Copy Download .nbib Format: NLM
editor's comments.

The International journal of biological markers

Gion M, Fabricio AS.
PMID: 28207122
Int J Biol Markers. 2008 Apr - Jun;23(2):67-68. doi: 10.5301/JBM.2008.1138.

no abstract.

Cite
Gion M, Fabricio AS. editor's comments. Int J Biol Markers. 2008;23(2):67-68doi: 10.5301/JBM.2008.1138.
Gion, M., & Fabricio, A. S. (2008). editor's comments. The International journal of biological markers, 23(2), 67-68. https://doi.org/10.5301/JBM.2008.1138
Gion, M, and Fabricio, A S C. "editor's comments." The International journal of biological markers vol. 23,2 (2008): 67-68. doi: https://doi.org/10.5301/JBM.2008.1138
Gion M, Fabricio AS. editor's comments. Int J Biol Markers. 2008 Apr - Jun;23(2):67-68. doi: 10.5301/JBM.2008.1138. PMID: 28207122.
Copy Download .nbib Format: NLM
Behavior of free testosterone in patients with prostate cancer on androgen deprivation therapy.

The International journal of biological markers

Morote J, Esquena S, Abascal JM, Trilla E, Cecchini L, Ravents CX, Cataln R, Revents J.
PMID: 28207137
Int J Biol Markers. 2005 Apr - Jun;20(2):119-222. doi: 10.5301/JBM.2008.1427.

OBJECTIVES: Determination of free testosterone (FT) serum level is an efficient method to evaluate bioavailable testosterone. We analyzed the behavior of serum FT in patients with prostate cancer receiving androgen deprivation therapy (ADT) and correlated FT with total testosterone...

Cite
Morote J, Esquena S, Abascal JM, et al. Behavior of free testosterone in patients with prostate cancer on androgen deprivation therapy. Int J Biol Markers. 2005;20(2):119-222doi: 10.5301/JBM.2008.1427.
Morote, J., Esquena, S., Abascal, J. M., Trilla, E., Cecchini, L., Ravents, C. X., Cataln, R., & Revents, J. (2005). Behavior of free testosterone in patients with prostate cancer on androgen deprivation therapy. The International journal of biological markers, 20(2), 119-222. https://doi.org/10.5301/JBM.2008.1427
Morote, J, et al. "Behavior of free testosterone in patients with prostate cancer on androgen deprivation therapy." The International journal of biological markers vol. 20,2 (2005): 119-222. doi: https://doi.org/10.5301/JBM.2008.1427
Morote J, Esquena S, Abascal JM, Trilla E, Cecchini L, Ravents CX, Cataln R, Revents J. Behavior of free testosterone in patients with prostate cancer on androgen deprivation therapy. Int J Biol Markers. 2005 Apr - Jun;20(2):119-222. doi: 10.5301/JBM.2008.1427. PMID: 28207137.
Copy Download .nbib Format: NLM
The effect of venous thromboembolism on survival of cancer patients and its relationship with serum levels of factor VIII and vascular endothelial growth factor: a prospectivematched-paired study.

The International journal of biological markers

Dogan M, Demirkazik A, Konuk N, Yalcin B, Buyukcelik A, Utkan G, Tek I, Akbulut H, Sencan O, Icli F.
PMID: 28207147
Int J Biol Markers. 2006 Oct - Dec;21(4):206-210. doi: 10.5301/JBM.2008.4592.

BACKGROUND: Venous thromboembolism (VT) increases mortality and morbidity in cancer patients. The primary aim of this study was to evaluate the effect of VT on the survival of cancer patients and its relationship with serum vascu-lar endothelial growth factor...

Cite
Dogan M, Demirkazik A, Konuk N, et al. The effect of venous thromboembolism on survival of cancer patients and its relationship with serum levels of factor VIII and vascular endothelial growth factor: a prospectivematched-paired study. Int J Biol Markers. 2006;21(4):206-210doi: 10.5301/JBM.2008.4592.
Dogan, M., Demirkazik, A., Konuk, N., Yalcin, B., Buyukcelik, A., Utkan, G., Tek, I., Akbulut, H., Sencan, O., & Icli, F. (2006). The effect of venous thromboembolism on survival of cancer patients and its relationship with serum levels of factor VIII and vascular endothelial growth factor: a prospectivematched-paired study. The International journal of biological markers, 21(4), 206-210. https://doi.org/10.5301/JBM.2008.4592
Dogan, M, et al. "The effect of venous thromboembolism on survival of cancer patients and its relationship with serum levels of factor VIII and vascular endothelial growth factor: a prospectivematched-paired study." The International journal of biological markers vol. 21,4 (2006): 206-210. doi: https://doi.org/10.5301/JBM.2008.4592
Dogan M, Demirkazik A, Konuk N, Yalcin B, Buyukcelik A, Utkan G, Tek I, Akbulut H, Sencan O, Icli F. The effect of venous thromboembolism on survival of cancer patients and its relationship with serum levels of factor VIII and vascular endothelial growth factor: a prospectivematched-paired study. Int J Biol Markers. 2006 Oct - Dec;21(4):206-210. doi: 10.5301/JBM.2008.4592. PMID: 28207147.
Copy Download .nbib Format: NLM
The role of single nucleotide polymorphisms of miRNAs 100 and 146a as prognostic factors for prostate cancer.

The International journal of biological markers

Camargo JA, Lopes RE, Ferreira GFD, Viana NI, Guimaraes V, Leite KRM, Nahas WC, Srougi M, Antunes AA, Reis ST.
PMID: 34030497
Int J Biol Markers. 2021 Jun;36(2):50-56. doi: 10.1177/1724600821997461. Epub 2021 May 25.

INTRODUCTION: Prostate cancer has a high incidence in men and is the second cause of cancer death among americans male. microRNA (miR) is becoming a potential new prognostic factor for prostate cancer. Single nucleotide polymorphisms (SNPs) are common polymorphisms,...

Cite
Camargo JA, Lopes RE, Ferreira GFD, et al. The role of single nucleotide polymorphisms of miRNAs 100 and 146a as prognostic factors for prostate cancer. Int J Biol Markers. 2021;36(2):50-56doi: 10.1177/1724600821997461.
Camargo, J. A., Lopes, R. E., Ferreira, G. F. D., Viana, N. I., Guimaraes, V., Leite, K. R. M., Nahas, W. C., Srougi, M., Antunes, A. A., & Reis, S. T. (2021). The role of single nucleotide polymorphisms of miRNAs 100 and 146a as prognostic factors for prostate cancer. The International journal of biological markers, 36(2), 50-56. https://doi.org/10.1177/1724600821997461
Camargo, Juliana Alves de, et al. "The role of single nucleotide polymorphisms of miRNAs 100 and 146a as prognostic factors for prostate cancer." The International journal of biological markers vol. 36,2 (2021): 50-56. doi: https://doi.org/10.1177/1724600821997461
Camargo JA, Lopes RE, Ferreira GFD, Viana NI, Guimaraes V, Leite KRM, Nahas WC, Srougi M, Antunes AA, Reis ST. The role of single nucleotide polymorphisms of miRNAs 100 and 146a as prognostic factors for prostate cancer. Int J Biol Markers. 2021 Jun;36(2):50-56. doi: 10.1177/1724600821997461. Epub 2021 May 25. PMID: 34030497.
Copy Download .nbib Format: NLM
The association of hepatitis C virus infection and thyroid disease: A systematic review and meta-analysis.

The International journal of biological markers

Wang H, Liu Y, Zhao Y.
PMID: 34825832
Int J Biol Markers. 2021 Dec;36(4):3-9. doi: 10.1177/17246008211056959. Epub 2021 Nov 26.

Previous studies have reported that hepatitis C virus (HCV) infection may increase the risk of thyroid disease (TD) even thyroid cancer (TC), but quantitative assessments of risk were rare and the results were not consistent. The purpose of this...

Cite
Wang H, Liu Y, Zhao Y. The association of hepatitis C virus infection and thyroid disease: A systematic review and meta-analysis. Int J Biol Markers. 2021;36(4):3-9doi: 10.1177/17246008211056959.
Wang, H., Liu, Y., & Zhao, Y. (2021). The association of hepatitis C virus infection and thyroid disease: A systematic review and meta-analysis. The International journal of biological markers, 36(4), 3-9. https://doi.org/10.1177/17246008211056959
Wang, Hongpeng, et al. "The association of hepatitis C virus infection and thyroid disease: A systematic review and meta-analysis." The International journal of biological markers vol. 36,4 (2021): 3-9. doi: https://doi.org/10.1177/17246008211056959
Wang H, Liu Y, Zhao Y. The association of hepatitis C virus infection and thyroid disease: A systematic review and meta-analysis. Int J Biol Markers. 2021 Dec;36(4):3-9. doi: 10.1177/17246008211056959. Epub 2021 Nov 26. PMID: 34825832.
Copy Download .nbib Format: NLM
SOX2 as a prognostic marker and a potential molecular target in cervical cancer: A meta-analysis.

The International journal of biological markers

Yuan D, Wang J, Yan M, Xu Y.
PMID: 34719977
Int J Biol Markers. 2021 Dec;36(4):45-53. doi: 10.1177/17246008211042899. Epub 2021 Oct 30.

BACKGROUND: Sex determining region Y-box 2 (SOX2) has been reported as a potential therapeutic target for cancer. However, the role of SOX2 in cervical cancer remains largely undetermined. This study was performed to evaluate the correlation of SOX2 with...

Cite
Yuan D, Wang J, Yan M, et al. SOX2 as a prognostic marker and a potential molecular target in cervical cancer: A meta-analysis. Int J Biol Markers. 2021;36(4):45-53doi: 10.1177/17246008211042899.
Yuan, D., Wang, J., Yan, M., & Xu, Y. (2021). SOX2 as a prognostic marker and a potential molecular target in cervical cancer: A meta-analysis. The International journal of biological markers, 36(4), 45-53. https://doi.org/10.1177/17246008211042899
Yuan, Dandan, et al. "SOX2 as a prognostic marker and a potential molecular target in cervical cancer: A meta-analysis." The International journal of biological markers vol. 36,4 (2021): 45-53. doi: https://doi.org/10.1177/17246008211042899
Yuan D, Wang J, Yan M, Xu Y. SOX2 as a prognostic marker and a potential molecular target in cervical cancer: A meta-analysis. Int J Biol Markers. 2021 Dec;36(4):45-53. doi: 10.1177/17246008211042899. Epub 2021 Oct 30. PMID: 34719977.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 119 entries